Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: GlobeNewswire
- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of Pulmonary Fibrosis CUPERTINO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced European Patent 3749324 has been granted by the European Patent Office (EPO) covering use of brilaroxazine for the treatment of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF), adding to its existing patent protection in key markets around the world including the United States, China and Jap
Show less
Read more
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
- Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.MarketBeat
- Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025GlobeNewswire
- Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis [Yahoo! Finance]Yahoo! Finance
- Reviva to Participate in the Spartan Capital Securities Second Annual Investor ConferenceGlobeNewswire
RVPH
Earnings
- 11/13/25 - Beat
RVPH
Sec Filings
- 12/5/25 - Form DEFA14A
- 11/4/25 - Form ARS
- 11/4/25 - Form DEFA14A
- RVPH's page on the SEC website